{"filing":{"accession_number":"0000920148-26-000182","cik":"0000920148","ticker":"LH","company_name":"LABCORP HOLDINGS INC.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-11","primary_document":"lh-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014826000182/lh-20260811.htm"},"events":[{"id":27784,"run_id":25358,"accession_number":"0000920148-26-000182","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Megan D. Bailey's resignation as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026, is the principal disclosed action. While the filing also describes Brian J. Caveney's assumption of expanded responsibilities, the core event triggering the 8-K disclosure is Bailey's departure from a senior executive role. The departure of a named executive officer at this level is material to investors.","company_name":"LABCORP HOLDINGS INC.","ticker":"LH","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29460,"accession_number":"0000920148-26-000182","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Megan D. Bailey's resignation as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026, is the principal disclosed action. While the filing also describes Brian J. Caveney's assumption of expanded responsibilities, the core event triggering the 8-K disclosure is Bailey's departure from a senior executive role. The departure of a named executive officer at this level is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:56:36.303466+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29460,"accession_number":"0000920148-26-000182","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Megan D. Bailey's resignation as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026, is the principal disclosed action. While the filing also describes Brian J. Caveney's assumption of expanded responsibilities, the core event triggering the 8-K disclosure is Bailey's departure from a senior executive role. The departure of a named executive officer at this level is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:56:36.303466+00:00","company_name":"LABCORP HOLDINGS INC.","ticker":"LH","filing_date":"2026-08-14"}]}